Clinical Trial Update: Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients [Phase 2]

View source ↗

Summary

Phase II trial evaluating fruquintinib in combination with sintilimab for refractory metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Aiping Zhou | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN